Global Search | Novartis

Hide Filters

Showing 2714 results

Press Release / Oct 16, 2018

Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis

Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] …
Ad-hoc Releases / Oct 18, 2018

Novartis a enregistré, au troisième trimestre, une forte croissance et fait preuve d'une innovation dynamique, incluant des plateformes thérapeutiques avancées pour soutenir la croissance future

Hausse du chiffre d'affaires net de 6% (tcc[1], +3% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 750 millions (+37% tcc) grâce à une forte croissance en volume dans toutes…
Ad-hoc Releases / Oct 18, 2018

Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth

Net sales grew 6% (cc[1], +3% USD) mainly driven by: Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications Entresto more than doubled to USD 271 million (+113…
Press Release / Oct 19, 2018

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

Lutathera treatment was associated with an ~80% reduction in the estimated risk of tumor progression or death vs comparator, regardless of baseline liver tumor burden[1] Lutathera treatment was…
Ad-hoc Releases / Oct 18, 2018

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms

Novartis to acquire Endocyte to accelerate development of innovative radioligand technology for treating cancer Acquisition would add 177Lu-PSMA-617, a potential first-in-class…
Press Release / Oct 20, 2018

Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone

In SOLAR-1 trial, BYL719 plus fulvestrant significantly improved PFS and ORR in these patients, following progression on or after an aromatase inhibitor with or without a CDK4/6 inhibitor, vs.…
Press Release / Oct 19, 2018

Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC

Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small…
Press Release / Oct 22, 2018

Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma

Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of…
Press Release / Oct 23, 2018

Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed

The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported…
Press Release / Oct 23, 2018

Alcon to develop SMART Suite digital health platform for cataract surgery

SMART Suite by Alcon will drive innovation in ophthalmology delivering personalized and seamless end-to-end care for cataract patients As an open, secure cloud-enabled ecosystem, SMART…